Evotec To Acquire Rigenerand For EUR 23 Mln
businessinsider.com
finance
2022-05-30 07:42:13

(RTTNews) - Evotec agreed to acquire 100% of the capital of Rigenerand Srl, a cell technology company, for 23 million euros. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a pioneering company in the field of cGMP manufacturing of cell therapies. Rigenerand is based in Medolla, Italy, about 100 km south of Evotec's Campus Levi-Montalcini in Verona. The production facility, called "cell factory", comprises a series of fully equipped clean rooms for the manufacturing of complex cell-based therapies.
